Share on StockTwits

Spectrum Pharmaceuticals (NASDAQ:SPPI)‘s stock had its “positive” rating restated by research analysts at Roth Capital in a report released on Monday.

Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Spectrum Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Thursday, June 5th. They now have a $8.60 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $11.72.

Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) opened at 8.90 on Monday. Spectrum Pharmaceuticals has a 1-year low of $6.36 and a 1-year high of $10.32. The stock has a 50-day moving average of $8.09 and a 200-day moving average of $8.07. The company’s market cap is $564.7 million.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.01 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.22) by $0.23. The company had revenue of $40.10 million for the quarter, compared to the consensus estimate of $39.49 million. During the same quarter last year, the company posted $0.01 earnings per share. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. Analysts expect that Spectrum Pharmaceuticals will post $-0.70 EPS for the current fiscal year.

Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.